www.idosr.org
©IDOSR PUBLICATIONS
Ssenkayi, 2024
ISSN: 2579-079X
International Digital Organization for Scientific Research
IDOSR JST/24/10.81200
IDOSR JOURNAL OF SCIENCE AND TECHNOLOGY 10(2):8-12, 2024.
https://doi.org/10.59298/IDOSR/JST/24/102.81200

Activation in Autoimmunity: Mechanisms and Clinical Implications

Ssenkayi Julius

Faculty of Pharmacy Kampala International University Uganda

Email:Julius.ssenkayi@studwc.kiu.ac.ug

ABSTRACT

Autoimmunity arises when the immune system mistakenly targets the body's own tissues, leading to chronic inflammatory diseases that can affect multiple organs. The central event in autoimmunity is the inappropriate activation of immune cells, which normally tolerate self-antigens. This review examines the mechanisms underlying immune activation in autoimmunity, focusing on the loss of immune tolerance, molecular mimicry, bystander activation, and epitope spreading. Genetic predispositions and environmental triggers, such as infections, play key roles in this process, contributing to the dysregulation of immune responses. Specific immune cells, including autoreactive T cells, B cells producing autoantibodies, and dendritic cells presenting self-antigens, drive disease pathogenesis by perpetuating inflammation and tissue damage. Dysfunctions in regulatory T cells (Tregs) further exacerbate immune activation by failing to suppress autoreactive lymphocytes. Clinically, understanding these activation mechanisms is crucial for developing diagnostic biomarkers and targeted therapies. Current treatments focus on modulating immune responses through biologic agents that block pro-inflammatory cytokines (e.g., TNF-α, IL-6), deplete B cells (e.g., rituximab), or restore immune regulation (e.g., Treg therapies). Emerging therapies aim to restore immune tolerance, offering hope for more effective and personalized interventions. This review highlights the critical role of immune activation in autoimmunity and discusses therapeutic strategies to prevent or reverse this process. The ongoing exploration of these mechanisms is key to improving outcomes for patients with autoimmune diseases.

Keywords: Autoimmunity, immune tolerance, molecular mimicry, T cells, autoantibodies, targeted therapy

INTRODUCTION

Autoimmunity arises when the immune system mistakenly targets the body's own tissues, leading to chronic inflammatory diseases that can affect various organs. A central aspect of this process is the inappropriate activation of immune cells, which normally remain tolerant of self-antigens [1]. This review explores the mechanisms behind immune activation in autoimmunity, emphasizing the pathways leading to loss of immune tolerance and the role of specific immune cells, including autoreactive T and B cells, in driving disease. Genetic predisposition and environmental triggers, such as infections, often contribute to the breakdown of tolerance, resulting in the activation of autoreactive lymphocytes and the production of autoantibodies [2]. Key mechanisms like molecular mimicry, bystander activation, and epitope spreading perpetuate these autoimmune responses. Clinically, this dysregulation leads to conditions such as rheumatoid arthritis, lupus, and type 1 diabetes [3]. Understanding these mechanisms is crucial for advancing treatments aimed at modulating immune activation and restoring immune tolerance. Current therapies include biologics targeting cytokines and immune cells involved in inflammation, while emerging treatments focus on re-establishing tolerance, offering hope for more effective and personalized approaches to autoimmune disease management.

Introduction to Autoimmune Activation

Autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA),

multiple sclerosis (MS), and type 1 diabetes (T1D), arise when the immune system's regulatory mechanisms fail, allowing the activation of autoreactive lymphocytes [4]. These activated immune cells recognize and attack the body's own tissues, leading to inflammation, tissue damage, and chronic disease. The pathogenesis of autoimmune disorders is complex and involves genetic susceptibility, environmental triggers, and dysregulation of immune tolerance mechanisms. Autoimmune activation typically arises from a combination of genetic predispositions and environmental factors, including infections, hormonal changes, and environmental toxins [1]. Certain genetic polymorphisms, particularly in genes related to immune regulation such as those encoding human leukocyte antigen (HLA) proteins, increase susceptibility to autoimmunity by affecting how self-antigens are presented to immune cells [5]. Environmental triggers, including viral infections, can initiate immune activation by molecular mimicry, where foreign antigens resemble self-antigens, or by causing the release of normally sequestered self-antigens, leading to immune recognition and attack [6].

MECHANISMS OF IMMUNE ACTIVATION IN AUTOIMMUNITY

Loss of Immune Tolerance

Immune tolerance refers to the immune system's ability to recognize and ignore the body's own cells and proteins, preventing harmful immune responses against self-antigens [7]. In autoimmunity, this tolerance is lost, and autoreactive T and B cells become activated. This loss of tolerance can occur through several mechanisms:

Central tolerance: During immune cell development in the thymus (for T cells) and bone marrow (for B cells), self-reactive cells are normally eliminated. Failures in this process can allow autoreactive lymphocytes to escape into the peripheral circulation [8].

Peripheral tolerance: Even if self-reactive cells escape central tolerance, they can be rendered inactive in peripheral tissues by regulatory mechanisms such as T regulatory cells (Tregs), anergy (functional inactivation), or deletion [9]. A breakdown in peripheral tolerance, often due to defective Treg function, can lead to the activation of autoreactive cells [10].

Molecular Mimicry

Molecular mimicry is one of the most widely studied mechanisms that can trigger autoimmune activation. It occurs when foreign antigens, such as those from pathogens, share structural similarities with self-antigens [11]. The immune system, while targeting the foreign pathogen, can also cross-react with self-tissues. For example, in rheumatic fever, antibodies generated against *Streptococcus* bacteria cross-react with heart tissue, leading to inflammation and damage [12]. In multiple sclerosis, it is suggested that viral infections might trigger immune responses against myelin, the protective sheath around nerves [13].

Bystander Activation

Bystander activation occurs when an infection or inflammatory event leads to the activation of autoreactive lymphocytes in the vicinity of inflammation, even though they are not specific to the pathogen causing the infection [14]. Inflammation causes the release of pro-inflammatory cytokines, like interferons and interleukins, which can enhance the activation of nearby autoreactive T and B cells, thus promoting autoimmunity. This mechanism is proposed in autoimmune diseases such as type 1 diabetes, where viral infections can trigger an autoimmune response against insulin-producing beta cells [15].

Epitope Spreading

Epitope spreading refers to the process where the initial immune response against a specific antigen expands to target additional epitopes on the same or different proteins. This mechanism is particularly relevant in autoimmune diseases like lupus, where the initial immune response against a specific nuclear antigen (e.g., histones) can spread to target other nuclear components such as DNA and RNA-binding proteins [16]. This leads to a progressive and expanding autoimmune attack that exacerbates disease severity.

KEY IMMUNE CELLS INVOLVED IN AUTOIMMUNE ACTIVATION

T Cells

T cells, particularly autoreactive CD4+ helper T cells, are central to the pathogenesis of many autoimmune diseases. These cells recognize self-antigens presented by antigen-presenting cells (APCs) via major histocompatibility complex (MHC) molecules [17]. Once activated, autoreactive T cells can orchestrate immune responses by producing pro-inflammatory cytokines, such as interferon-gamma (IFN-γ) and interleukin-17 (IL-17), which recruit other immune cells and perpetuate inflammation. In autoimmune diseases like multiple sclerosis and rheumatoid arthritis, CD4+ T cells play a critical role in driving tissue damage. Regulatory T cells (Tregs), which normally suppress autoreactive T cell responses, are often

dysfunctional in autoimmune conditions, allowing unchecked activation of autoreactive T cells [18]. Restoring Treg function or enhancing their suppressive capabilities is a promising therapeutic strategy for many autoimmune diseases.

B Cells and Autoantibodies

B cells play a crucial role in autoimmunity by producing autoantibodies—antibodies that target self-antigens. Autoantibodies contribute to tissue damage by forming immune complexes that deposit in tissues, activating the complement system, and recruiting inflammatory cells [19]. In systemic lupus erythematosus (SLE), for example, autoantibodies against DNA and nuclear proteins are a hallmark of the disease, leading to widespread tissue inflammation and damage. In addition to producing autoantibodies, B cells can also act as antigen-presenting cells, presenting self-antigens to autoreactive T cells and further amplifying the autoimmune response. Targeting B cells with therapies like rituximab (anti-CD20 monoclonal antibody) has been effective in treating certain autoimmune diseases by depleting B cells and reducing autoantibody production [20].

Dendritic Cells

Dendritic cells (DCs) are professional antigen-presenting cells that play a pivotal role in initiating immune responses. In autoimmune diseases, dendritic cells can aberrantly present self-antigens to T cells, leading to their activation [21]. Certain dendritic cell subsets, particularly plasmacytoid dendritic cells (pDCs), are known to produce large amounts of type I interferons, which contribute to the chronic inflammation seen in diseases like lupus [22]. Modulating dendritic cell function and their ability to present antigens is an area of active research for autoimmune therapies.

CLINICAL IMPLICATIONS OF AUTOIMMUNE ACTIVATION

Understanding the mechanisms of immune activation in autoimmunity has important clinical implications for the diagnosis, treatment, and management of autoimmune diseases.

Biomarkers for Diagnosis and Prognosis

The identification of autoantibodies, cytokine profiles, and specific T cell populations has improved the ability to diagnose autoimmune diseases and predict disease progression. For example, the presence of anti-citrullinated protein antibodies (ACPAs) is highly specific for rheumatoid arthritis and can be detected before clinical symptoms appear, allowing for earlier diagnosis and intervention [23]. Similarly, measuring levels of specific cytokines, like IFN-α in lupus patients, can serve as a biomarker for disease activity and help guide treatment decisions.

Targeted Therapies

The elucidation of immune activation pathways has led to the development of targeted therapies that aim to modulate the immune response. Biologic agents, such as monoclonal antibodies, have revolutionized the treatment of autoimmune diseases by specifically targeting cytokines, immune cells, or receptors involved in the pathogenic process [24].

Anti-TNF Therapy: In diseases like rheumatoid arthritis, Crohn's disease, and psoriasis, anti-tumor necrosis factor (TNF) agents, such as infliximab and adalimumab, have been highly effective in reducing inflammation and preventing disease progression by blocking the action of TNF-α, a pro-inflammatory cytokine central to autoimmune activation [25].

IL-6 and IL-17 Blockade: Agents targeting IL-6 (e.g., tocilizumab) and IL-17 (e.g., secukinumab) have shown efficacy in treating autoimmune diseases like rheumatoid arthritis and ankylosing spondylitis by inhibiting key cytokines involved in driving inflammation [26].

B Cell Depletion: Rituximab, an anti-CD20 monoclonal antibody that depletes B cells, has been used successfully to treat autoimmune diseases such as SLE and rheumatoid arthritis by reducing autoantibody production and B cell-mediated antigen presentation [28].

Emerging Therapies

New therapeutic strategies are being developed that aim to restore immune tolerance rather than merely suppress inflammation. These include therapies that expand or enhance the function of T regulatory cells, tolerogenic dendritic cells, and antigen-specific immunotherapies that aim to reset the immune system's recognition of self-antigens [27].

CONCLUSION

The activation of autoreactive immune cells is a central feature of autoimmune diseases, driven by complex interactions between genetic predisposition, environmental triggers, and immune dysregulation. Understanding the molecular and cellular mechanisms behind immune activation has led to significant advances in the diagnosis and treatment of autoimmune disorders. Targeted therapies that modulate specific pathways involved in immune activation hold great promise for improving outcomes in autoimmune diseases, though restoring immune tolerance remains the ultimate goal. Ongoing research into the mechanisms of autoimmune activation will continue to drive the

development of novel therapies, potentially offering more personalized.

REFERENCES

1. Yasmeen F, Pirzada RH, Ahmad B, Choi B, Choi S. Understanding Autoimmunity: Mechanisms, Predisposing Factors, and Cytokine Therapies. International Journal of Molecular Sciences. 2024; Jul 12;25(14):7666.
2. Pisetsky, D. S. Pathogenesis of autoimmune disease. *Nature Reviews Nephrology*, 2023; *19*(8), 509-524.
3. Alum, E. U., Ibiam, U. A., Ugwuja, E. I., Aja, P. M., Igwenyi, I. O., et al. Antioxidant Effect of *Buchholzia coriacea* Ethanol Leaf Extract and Fractions on Freund's Adjuvant-induced Arthritis in Albino Rats: A Comparative Study. *Slovenian Veterinary Research.* 2022; 59 (1): 31–45. doi: 10.26873/svr-1150-2022.
4. Cuthrell KM, Tzenios N, Umber J. Burden of Autoimmune Disorders; a review. Asian Journal of Immunology. 2022; 6(3):1-3.
5. Abd Ali EH, Mohammed HO. Autoimmune Disorders Unraveled: The Interplay Between Genetics and the Immune System. International Journal of Medical Science and Dental Health. 2024; 10(03):01-14.
6. Wildner G, Diedrichs-Möhring M. Molecular mimicry and uveitis. Frontiers in Immunology. 2020; 11:580636.
7. Goldfarb Y, Peligero-Cruz C, Abramson J. Immunological Tolerance—T Cells. InThe Autoimmune Diseases 2020; Jan 1 (pp. 65-90). Academic Press.
8. Sharma SK. T Cell Development. InBasics of Hematopoietic Stem Cell Transplant 2023; Jul 21 (pp. 31-58). Singapore: Springer Nature Singapore.
9. Goverman JM. Immune tolerance in multiple sclerosis. Immunol Rev. 2011; 241(1):228-40. doi: 10.1111/j.1600-065X.2011.01016.x.
10. Sogkas G, Atschekzei F, Adriawan IR, Dubrowinskaja N, Witte T, Schmidt RE. Cellular and molecular mechanisms breaking immune tolerance in inborn errors of immunity. Cellular & Molecular Immunology. 2021; 18(5):1122-40.
11. Suliman BA. Potential clinical implications of molecular mimicry-induced autoimmunity. Immunity, Inflammation and Disease. 2024; 12(2):e1178.
12. Guilherme L, Steer AC, Cunningham M. Pathogenesis of acute rheumatic fever. InAcute Rheumatic Fever and Rheumatic Heart Disease 2021 Jan 1 (pp. 19-30). Elsevier.
13. Tarlinton RE, Martynova E, Rizvanov AA, Khaiboullina S, Verma S. Role of viruses in the pathogenesis of multiple sclerosis. Viruses. 2020; 12(6):643.
14. Sundaresan B, Shirafkan F, Ripperger K, Rattay K. The role of viral infections in the onset of autoimmune diseases. Viruses. 2023; 15(3):782.
15. Bennett JM, Reeves G, Billman GE, Sturmberg JP. Inflammation–nature's way to efficiently respond to all types of challenges: implications for understanding and managing "the epidemic" of chronic diseases. Frontiers in medicine. 2018; 5:316.
16. Pisetsky DS. Evolving story of autoantibodies in systemic lupus erythematosus. Journal of autoimmunity. 2020; 110:102356.
17. Rojas M, Acosta-Ampudia Y, Heuer LS, Zang W, Monsalve DM, Ramírez-Santana C, Anaya JM, Ridgway WM, Ansari AA, Gershwin ME. Antigen-specific T cells and autoimmunity. Journal of Autoimmunity. 2024; 148:103303.
18. Goswami TK, Singh M, Dhawan M, Mitra S, Emran TB, Rabaan AA, Mutair AA, Alawi ZA, Alhumaid S, Dhama K. Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders–Advances and challenges. Human vaccines & immunotherapeutics. 2022; 18(1):2035117.
19. Lin X, Lu L. B cell-mediated autoimmune diseases. B cells in immunity and tolerance. 2020: 145-60.
20. Crickx E, Weill JC, Reynaud CA, Mahévas M. Anti-CD20–mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives. Kidney International. 2020; 97(5):885-93.
21. Tarbell KV, Rahman MJ. Dendritic cells in autoimmune disease. InThe autoimmune diseases 2020 Jan 1 (pp. 213-227). Academic Press.
22. Ye Y, Gaugler B, Mohty M, Malard F. Plasmacytoid dendritic cell biology and its role in immune mediated diseases. Clinical & translational immunology. 2020; 9(5):e1139.
23. Wu CY, Yang HY, Lai JH. Anti-citrullinated protein antibodies in patients with rheumatoid arthritis: biological effects and mechanisms of immunopathogenesis. International Journal of Molecular Sciences. 2020; 21(11):4015.
24. Takeuchi T. Cytokines and cytokine receptors as targets of immune-mediated inflammatory

diseases—RA as a role model. Inflammation and regeneration. 2022; 42(1):35.
25. Leone GM, Mangano K, Petralia MC, Nicoletti F, Fagone P. Past, present and (foreseeable) future of biological anti-TNF alpha therapy. Journal of Clinical Medicine. 2023; 12(4):1630.
26. Raychaudhuri SP, Raychaudhuri SK. Mechanistic rationales for targeting interleukin-17A in spondyloarthritis. Arthritis research & therapy. 2017; 19:1-9.
27. Alum, E. U., Ibiam, U. A. and Ugwu, O. P. C. A Comprehensive Review of Treatment Approaches and Perspectives for Management of Rheumatoid Arthritis. *INOSR Scientific Research*. 2023; 10(1):12-17. https://doi.org/10.59298/INOSRSR/2023/2.2.13322
28. Moorman CD, Sohn SJ, Phee H. Emerging therapeutics for immune tolerance: tolerogenic vaccines, T cell therapy, and IL-2 therapy. Frontiers in immunology. 2021; 12:657768.

CITE AS: Ssenkayi Julius (2024). Activation in Autoimmunity: Mechanisms and Clinical Implications. IDOSR JOURNAL OF SCIENCE AND TECHNOLOGY 10(2):8-12. https://doi.org/10.59298/IDOSR/JST/24/102.81200